Arrowhead Pharmaceuticals
Utility Patents
Last updated:
List of all Arrowhead Pharmaceuticals patents 25 in total
| Status | Patent |
|---|---|
Grant | Utility: Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin Filling date: 8 Sep 2025 Issue date: 12 Jul 2022 |
Grant | Utility: Organic compositions to treat EPAS1-related diseases Filling date: 8 Sep 2025 Issue date: 1 Mar 2022 |
Grant | Utility: RNAi agents for inhibiting expression of alpha-ENaC and methods of use Filling date: 8 Sep 2025 Issue date: 4 Jan 2022 |
Grant | Utility: RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) Filling date: 8 Sep 2025 Issue date: 4 Jan 2022 |
Grant | Utility: RNAi inhibition of alpha-ENaC expression Filling date: 8 Sep 2025 Issue date: 28 Dec 2021 |
Grant | Utility: Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use Filling date: 8 Sep 2025 Issue date: 21 Dec 2021 |
Grant | Utility: Alpha-v beta-6 integrin ligands and uses thereof Filling date: 8 Sep 2025 Issue date: 23 Nov 2021 |
Grant | Utility: Targeting ligands Filling date: 8 Sep 2025 Issue date: 16 Nov 2021 |
Grant | Utility: Organic compositions to treat HSF1-related diseases Filling date: 8 Sep 2025 Issue date: 17 Aug 2021 |
Grant | Utility: 5'-cyclo-phosphonate modified nucleotides Filling date: 8 Sep 2025 Issue date: 3 Aug 2021 |
Grant | Utility: Organic compositions to treat APOC3-related diseases Filling date: 8 Sep 2025 Issue date: 20 Jul 2021 |
Grant | Utility: RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use Filling date: 8 Sep 2025 Issue date: 4 May 2021 |
Grant | Utility: Compositions and methods for inhibiting gene expression of Hif2alpha Filling date: 8 Sep 2025 Issue date: 23 Feb 2021 |
Grant | Utility: Compositions and methods for inhibiting gene expression of factor XII Filling date: 8 Sep 2025 Issue date: 8 Dec 2020 |
Grant | Utility: Compositions and methods for inhibiting gene expression of hepatitis B virus Filling date: 8 Sep 2025 Issue date: 8 Dec 2020 |
Grant | Utility: RNAi therapy for hepatitis B virus infection Filling date: 8 Sep 2025 Issue date: 20 Oct 2020 |
Grant | Utility: RNAi agents for Hepatitis B virus infection Filling date: 8 Sep 2025 Issue date: 22 Sep 2020 |
Grant | Utility: Compositions and methods for inhibiting gene expression of LPA Filling date: 8 Sep 2025 Issue date: 26 May 2020 |
Grant | Utility: Compositions and methods for inhibiting expression of RRM2 genes Filling date: 8 Sep 2025 Issue date: 14 Apr 2020 |
Grant | Utility: RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) Filling date: 8 Sep 2025 Issue date: 24 Mar 2020 |
Grant | Utility: RNAi agents for inhibiting expression of alpha-ENaC and methods of use Filling date: 8 Sep 2025 Issue date: 17 Mar 2020 |
Grant | Utility: Organic compositions to treat beta-ENaC-related diseases Filling date: 8 Sep 2025 Issue date: 4 Feb 2020 |
Grant | Utility: RNAi inhibition of alpha-ENaC expression Filling date: 8 Sep 2025 Issue date: 28 Jan 2020 |
Grant | Utility: Organic compositions to treat EPAS1-related diseases Filling date: 8 Sep 2025 Issue date: 21 Jan 2020 |
Grant | Utility: Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use Filling date: 8 Sep 2025 Issue date: 22 Oct 2019 |
Showing 1 to 25 of 25 patents.